Bank of America
ESLA icon

Bank of America’s Estrella Immunopharma ESLA Stock Holding History

Bank of America’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$16 – 6085
2025
Q4 		$16 Buy
10
+8
+400% +$15 ﹤0.01% 7160
2025
Q3 		$2 Sell
2
-90
-98% -$86 ﹤0.01% 8263
2025
Q2 		$89 Buy
92
+5
+6% +$5 ﹤0.01% 7986
2025
Q1 		$81 Buy
87
+4
+5% +$4 ﹤0.01% 7870
2024
Q4 		$100 Hold
83
– – ﹤0.01% 7732
2024
Q3 		$96 Buy
83
+5
+6% +$6 ﹤0.01% 7730
2024
Q2 		$82 Buy
+78
New +$80 ﹤0.01% 7745

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Bank of America's ESLA Position: Q1 2026 in Review

Bank of America sold out of Estrella Immunopharma (ESLA) in Q1 2026, closing a stake of 10 shares — an estimated $16 sold.

Bank of America first reported a position in ESLA in Q2 2024 and held it in 7 quarters. The position peaked at $100 in Q4 2024. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Bank of America reported no remaining Estrella Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 10 Estrella Immunopharma shares in Q1 2026, an estimated $16.
  • Bank of America first reported a position in Estrella Immunopharma in Q2 2024 and held it in 7 quarters.
  • Bank of America's Estrella Immunopharma position peaked at $100 in Q4 2024.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.